Proathlete Wealth Management’s AbbVie ABBV Stock Holding History

Proathlete Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Hold	984	–	–	0.06%	59
2026 Q1	$214K	Hold	984	–	–	0.06%	60
2025 Q4	$225K	Buy	984 +20	+2%	+$4.56K	0.06%	61
2025 Q3	$223K	Sell	964 -8	-0.8%	-$1.63K	0.06%	60
2025 Q2	$180K	Buy	972 +8	+0.8%	+$1.49K	0.06%	61
2025 Q1	$202K	Buy	+964	New	+$187K	0.07%	59

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Proathlete Wealth Management's ABBV Position: Q2 2026 in Review

Proathlete Wealth Management held its AbbVie (ABBV) position steady in Q2 2026 at 984 shares worth $248K. The position accounts for 0.06% of the portfolio, ranked #59.

Proathlete Wealth Management first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 1,043 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Proathlete Wealth Management held 984 shares of AbbVie worth $248K as of Q2 2026.
Proathlete Wealth Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.06% of Proathlete Wealth Management's portfolio in Q2 2026, its #59 holding.
Proathlete Wealth Management first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
1,043 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Proathlete Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.